Effect of Dupilumab on Onset of Type 1 Disease

Simple item page
dc.contributorChildren's Hospital of Philadelphia
dc.contributor.authorSpergel, Jonathan
dc.contributor.otherChildren's Hospital of Philadelphia
dc.date.accessioned2024-07-09T19:50:28Z
dc.date.available2024-07-09T19:50:28Z
dc.descriptionThis study investigates whether dupilumab, a Type 2 inflammation-blocking agent commonly used to treat allergic diseases, is associated with an increased risk of developing Type 1 diseases in children. Using the PEDSnet electronic health record network, researchers conducted a multicenter retrospective cohort study involving children aged 6-17 with asthma and/or atopic dermatitis, comparing those treated with dupilumab to those untreated and non-atopic children. The primary outcome was the diagnosis of Type 1 diseases, including conditions affecting the skin, endocrine, gastrointestinal, and other systems. The results showed that while overall rates of Type 1 disease diagnoses were low, dupilumab-treated children had a 1.9 times higher risk of developing Type 1 diseases within 4 years of treatment. Despite this increased risk, the findings suggest the need for further prospective studies to confirm the accuracy of these diagnoses and better understand the long-term side effects of dupilumab. #### Cohort Description Study sample consisted of three cohorts: 1. Children with atopic dermatitis and/or persistent asthma who have received therapy with dupilumab for at least 3 months. 2. A control population of children with atopic dermatitis and/or persistent asthma who are not treated with dupilumab. 3. A non-atopic control population of children without atopic dermatitis, asthma, or other atopic diseases who are not treated with dupilumab.
dc.description.abstractStudy to determine whether use of the Type 2 blocker dupilumab in children with atopic dermatitis and asthma is associated with increased frequency of developing Type 1 disease.
dc.identifier.urihttps://pedsnet.org/metadata/handle/20.500.14642/709
dc.publisherPEDSnet
dc.relationDupilumab
dc.relationPersistent Asthma
dc.relationAtopic Dermatitis
dc.relationEczema Topicals
dc.relationAnti-Asthmatic Agents
dc.rightsa CC-BY 4.0 Attribution license.
dc.rights.urihttps://creativecommons.org/licenses/by-sa/4.0/
dc.subjectStudy::Funded Study::PEDSnet Study
dc.subjectStudy::Investigator-Led Study
dc.subjectStudy::Cohort Study::Retrospective Study
dc.subject.meshdupilumab
dc.subject.meshInterleukin-4 Receptor alpha Antagonist
dc.subject.meshDermatitis, Atopic
dc.subject.meshAsthma
dc.titleEffect of Dupilumab on Onset of Type 1 Disease
dspace.entity.typeStudy
local.admin.note11/11 - potential for second phase/expansion of this study. https://chop365.sharepoint.com/:f:/r/teams/RSCH-ACRC/Shared%20Documents/PEDSnet/PEDSnet%20Studies/Active%20Studies/Spergel_T1%20Disease?csf=1&web=1&e=qio6yq
local.subject.flatPEDSnet Data Source
local.subject.flatInvestigator-Led Study
local.subject.flatCohort Study
local.subject.flatRetrospective Study
project.endDate2021-02
project.startDate2023-06
relation.isConceptSetOfStudy528e4d51-2293-4d4e-a1fb-97488ab557c9
relation.isConceptSetOfStudyee45e82b-4f4f-40a4-8372-addf1381360c
relation.isConceptSetOfStudy495283bc-acbe-4b7d-aaea-9be970f590cc
relation.isConceptSetOfStudy812c9423-2e60-478c-b402-7b41666a8969
relation.isConceptSetOfStudy5abf0a10-820b-4f3d-b9ae-56cf198cc3a2
relation.isConceptSetOfStudy.latestForDiscovery528e4d51-2293-4d4e-a1fb-97488ab557c9
relation.isOrgUnitOfStudyda841c56-bb55-405c-8b50-8f221ef62890
relation.isOrgUnitOfStudy.latestForDiscoveryda841c56-bb55-405c-8b50-8f221ef62890

Files

Domains

PEDSnet Designated Studies